Abdominal obesity type 2 diabetes
Conditions
Interventions
Proline combined with Gliclazide treatment group:NA
Sponsors
Shougang Shuigang Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years, regardless of gender; 2. Clinically diagnosed with type 2 diabetes (referencing the "Chinese Guidelines for the Prevention and Treatment of Diabetes (2024 Edition)"); 3. BMI >=24 kg/m²; 4. Assessed by a physician as suitable for treatment with proline plus glimepiride tablets; 5. Voluntarily participating in the study and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Moderate to severe renal impairment (eGFR =160 mmHg or diastolic BP >=100 mmHg); 3. Impaired liver function: ALT or AST >=3 times the upper limit of normal; 4. Acute or chronic metabolic acidosis, including diabetic ketoacidosis; 5. History of severe allergy to dapagliflozin, any excipient of this product, or any other SGLT-2 inhibitor; 6. Currently participating in, or has participated in, any other clinical trial within the past month; 7. Deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglycerides; | — |
Secondary
| Measure | Time frame |
|---|---|
| Glycated hemoglobin;Total cholesterol;High-density lipoprotein cholesterol;Low-density lipoprotein cholesterol;Fasting Blood Glucose;Blood sugar 2 hour after a meal;Body Mass Index;Alanine aminotransferase;Aspartate aminotransferase;Blood urea;Blood Creatinine;Blood uric acid; | — |
Countries
China
Contacts
Public ContactMin Zhang
Shougang Shuigang Hospital
Outcome results
None listed